Anti-Inflammatory Challenge in Schizophrenia

PHASE4RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Schizophrenia
Interventions
DRUG

Infliximab

"Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome. The current proposal represents the use of infliximab as an experimental tool to dissect the role of inflammatory processes leading to changes in brain reward circuitry and changes in specific symptom domains.~Double-blinded infusions of infliximab will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist."

DRUG

Placebo

Double-blinded infusions of saline will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.

Trial Locations (2)

30303

NOT_YET_RECRUITING

Grady Memorial Hospital, Atlanta

30322

RECRUITING

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Emory University

OTHER